Celemics, Inc.
Financials
Valuation Metrics
Celemics, Inc.'s Market Cap is ₩1262B. At end of 2025 it was ₩304B. Ranked #1137 of 2,421 in KR market (top 47%), #601 of 1,640 on KOSDAQ (top 37%), #130 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 56%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 126.24B KRW | KR#1,137/2,421 Sec#130/231 |
| Revenue | 5.22B KRW | KR#2,338/2,421 Sec#195/231 |
| Net Income | -10.18B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 48.78B KRW | KR#2,218/2,421 Sec#202/231 |
| Net Assets | 30.39B KRW | KR#2,172/2,421 Sec#194/231 |
| Employees | 42 | KR#2,116/2,421 Sec#195/231 |
| Value | ||
| P/B | 4.15x | KR#2,204/2,421 Sec#184/231 |
| P/S | 24.18x | KR#2,344/2,421 Sec#185/231 |
| FCF Yield | -2.98% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -33.50% | KR#2,211/2,421 Sec#184/231 |
| ROA | -20.87% | KR#2,250/2,421 Sec#179/231 |
| Op. Margin | -74.41% | KR#2,277/2,421 Sec#167/231 |
| Revenue Growth | -16.21% | KR#2,070/2,421 Sec#188/231 |
| Financial Health | ||
| Debt Ratio | 60.48% | KR#1,101/2,421 Sec#130/231 |
| Total Debt | 16.24B KRW | KR#1,463/2,421 Sec#121/231 |
| FCF | -3.76B KRW | KR#1,436/2,421 Sec#113/231 |
| Cash | 37.10B KRW | KR#886/2,421 Sec#58/231 |
| Current Ratio | 22.92x | KR#21/2,421 Sec#9/231 |
| Performance | ||
| 1Y Return | 264.19% | KR#30/2,421 Sec#1/231 |
| 1M Return | 25.58% | KR#172/2,421 Sec#12/231 |
| From 52W High | -43.09% | KR#1,064/2,421 Sec#75/231 |
| 1Y MDD | -53.96% | KR#1,165/2,421 Sec#97/231 |
| Trading | ||
| Volume | 56,871 shares | KR#1,069/2,421 Sec#105/231 |
| Trading Value | 628.5M KRW | KR#864/2,421 Sec#88/231 |
| Foreign Own. | 1.10% | KR#1,998/2,421 Sec#196/231 |
| Per Share | ||
| EPS | -911 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,718 KRW | KR#1,919/2,421 Sec#149/231 |
Company Info
CeleMix was established in 2010 to manufacture and analyze basic pharmaceutical substances and biological preparations, and was specially listed on the KOSDAQ market in 2020 as a technology growth company. This venture company specializes as an NGS-based gene analysis technology platform, producing and selling MSSIC-based Target Capture Kits and BTSeq sequencing solutions. It develops DNA-related cloning technologies through technology convergence across biotechnology, nanotechnology, and information technology, supplying essential materials to various sectors. CeleMix is headquartered in Geumcheon-gu, Seoul.